DexCom, Inc. (NASDAQ:DXCM) COO Jacob Steven Leach Sells 2,634 Shares

DexCom, Inc. (NASDAQ:DXCM) COO Jacob Steven Leach sold 2,634 shares of the company’s stock in a transaction on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total value of $228,920.94. Following the sale, the chief operating officer now owns 268,644 shares of the company’s stock, valued at approximately $23,347,850.04. The trade was a 0.97 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

DexCom Price Performance

Shares of NASDAQ DXCM opened at $87.62 on Friday. The company has a quick ratio of 2.12, a current ratio of 2.46 and a debt-to-equity ratio of 1.23. DexCom, Inc. has a fifty-two week low of $62.34 and a fifty-two week high of $142.00. The business has a 50 day moving average price of $80.22 and a two-hundred day moving average price of $76.59. The firm has a market cap of $34.22 billion, a PE ratio of 52.47, a price-to-earnings-growth ratio of 2.23 and a beta of 1.12.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on DXCM. Citigroup boosted their price target on DexCom from $85.00 to $91.00 and gave the company a “buy” rating in a research report on Wednesday, December 11th. Royal Bank of Canada dropped their target price on shares of DexCom from $120.00 to $115.00 and set an “outperform” rating for the company in a research report on Friday, October 25th. StockNews.com cut shares of DexCom from a “buy” rating to a “hold” rating in a research report on Saturday, November 2nd. Raymond James decreased their price objective on shares of DexCom from $115.00 to $99.00 and set a “strong-buy” rating for the company in a research note on Friday, October 25th. Finally, Wells Fargo & Company lifted their target price on shares of DexCom from $90.00 to $94.00 and gave the company an “overweight” rating in a report on Wednesday, December 11th. Five investment analysts have rated the stock with a hold rating, twelve have issued a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $99.29.

Hedge Funds Weigh In On DexCom

Several institutional investors and hedge funds have recently made changes to their positions in the business. Geode Capital Management LLC raised its holdings in DexCom by 2.2% in the third quarter. Geode Capital Management LLC now owns 9,937,604 shares of the medical device company’s stock valued at $664,056,000 after acquiring an additional 214,136 shares in the last quarter. Jennison Associates LLC increased its position in shares of DexCom by 10.3% in the 4th quarter. Jennison Associates LLC now owns 7,643,757 shares of the medical device company’s stock worth $594,455,000 after purchasing an additional 710,858 shares during the last quarter. Groupama Asset Managment raised its stake in shares of DexCom by 1.1% in the 3rd quarter. Groupama Asset Managment now owns 2,851,556 shares of the medical device company’s stock valued at $1,912,000 after purchasing an additional 31,358 shares in the last quarter. Westfield Capital Management Co. LP lifted its position in shares of DexCom by 44.6% during the third quarter. Westfield Capital Management Co. LP now owns 2,842,057 shares of the medical device company’s stock worth $190,532,000 after purchasing an additional 876,739 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its position in shares of DexCom by 11.8% during the third quarter. Charles Schwab Investment Management Inc. now owns 2,734,155 shares of the medical device company’s stock worth $183,298,000 after purchasing an additional 288,381 shares during the last quarter. 97.75% of the stock is currently owned by hedge funds and other institutional investors.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.